Ascendis Pharma A/s

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52